Step 1: The milestone agreement in June was to se

Step 1: The milestone agreement in June was to secure short term funding with a strong degree of confidence of success prior to 9/30/18 with THE key milestone being a royalty deal with Big Pharma for at least $10M upfront on B-OM. Sometime between the end of June and early August either that same Big Pharma or possibly a different Big Pharma approached IPIX and offered to partner to license both B-OM and B-IBD (and possibly the entire Brilacidin platform). Common sense dictates that with 2 or more instances this Term Sheet offer would provide higher amounts of upfront cash, higher milestone payments and a competitive royalty percentage on all future revenue. Once this Term Sheet agreement was signed off by both parties the previously PRed milestone announcement with Aspire was no longer needed and thus no longer the focus of IPIX management. Plug in your own numbers but I believe $50-$100M upfront, $100M+ milestone on Phase 3 completion and 15% royalties are realistic. I believe this Term Sheet agreement will be finalized sometime between this coming Monday and 12/1/18 with a WAG of mid- October. The Short Sellers will continue to control IPIX share price until that time at which point an announcement will be made and the IPIX share price will gap up in the $3-6 range depending on the dollars involved. I believe Leo is a smart businessman and has ample cash options in the event that this Term Sheet agreement gets delayed for any reason.